Navigation Links
Shorter treatment with hepatitis C drug combination may be more beneficial, study shows
Date:9/14/2011

CINCINNATIUniversity of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medicationa telaprevir-based regimen that is commonly used to treat the illnessfor 24 weeks were cured.

Usually, the treatment is administered for 48 weeks, and these results show that extended treatment is unnecessary, possibly changing the standard of care for hepatitis C patients. Researchers say this could mean better medication adherence as well as the decrease in side effects associated with longer medication use.

"Chronic infection with hepatitis C represents a serious health issue for nearly 200 million people worldwide," says Kenneth Sherman, MD, PhD, a UC Health digestive diseases expert, professor and chair of the division of digestive diseases at the UC College of Medicine and principal investigator of the study. "For many years, standard treatment of the type of hepatitis C most common in the United States required 48 weeks of treatment with two drugs: pegylated interferon and ribavirin. Sustained virologic response (cure) occurred in 40 to 50 percent of patients.

"In this clinical trial, we wanted to determine whether there was a group of patients that could be treated for a shorter period without sacrificing the response rate."

Hepatitis C is a viral disease that leads to inflammation of the liver. It can be spread through exchange of bodily fluids with an infected person.

In the study, 540 patients with hepatitis C who had not previously received treatment were enrolled. Seventy-two percent of all patients who entered the study had sustained viral response.

"The high viral cure rates showed that there was no benefit to extending the therapy to 48 weeks for the majority of people in this trial," Sherman says. "Importantly, patients in this trial had a high likelihood of achieving a cure with 24 weeks of total therapy if they had a rapid response to these regimens by week four. Knowing this may provide important motivation for people to continue therapy."

For this study, all patients received telaprevira protease inhibitor for hepatitis Cevery eight hours, peginterferon alfa-2a every week and ribavirin daily for 12 weeks. Then, telaprevir was stopped, and patients received just peginterferon-ribavirin until week 20.

Patients who had an extended rapid virologic response (undetectable hepatitis C virus RNA levels in their blood at four and 12 weeks) were randomly assigned after the 20th week to receive the pegylated interferon and ribavirin for either four or 28 more weeks. Patients without an extended rapid virologic response, who still had detectable hepatitis C, were automatically assigned to an additional 28 weeks

A total of 35265 percentof patients in the study had an extended rapid virologic response.

Among the patients with an extended rapid virologic response who were randomly assigned to receive the combination, 92 percent in the 24-week group and 88 percent in the 48-week group had a sustained virologic response of hepatitis C infection.

"These results are likely to change treatment standards for patients with hepatitis C and reduce adverse effects of the treatment regimen," adds Sherman.


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4553
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. For Some Breast Cancer Patients, Shorter Radiation Works Well
2. CT and MRI scans associated with shorter hospital stays and decreased costs
3. Shorter Hospital Stays May Hinder Heart Failure Patients
4. Shorter Telomere Length Again Linked to Cancer
5. The Longer You Sit, the Shorter Your Life Span: Study
6. Engineering shorter wait times in the ER
7. Study links shorter sleep durations with greater risks of mental distress in young adults
8. Shorter Sleep in Men Ups Risk of Heart Disease: Study
9. New findings on drug tolerance in TB suggest ideas for shorter cures
10. Shorter Hospital Stays, More Readmissions After Hip Replacements
11. Stress and depression are associated with shorter survival in head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... (PVDF) based sleep diagnostics sensors, announced today it had completed the first phase ... a mix of domestic and rest of world (ROW) authorized dealers specializing in ...
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , a ... CIO Applications magazine has named the company a “Top 25 Cybersecurity Companies 2017.” ... Cloud to help organizations simply and proactively address potential cybersecurity threats before they happen. ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... and medical device sectors, today announced the winners of its 3rd Annual ELITE ... the most influential people in the healthcare industry today. , Out of more ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... The ... professionals, is pleased to announce the organization’s Certified Strength Coach credential has earned ... Strength Coach (CSC) program validates the competency of qualified candidates for jobs in ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... WASHINGTON , May 10, 2017  The ... doctors or employees of sleep therapy clinics to ... a sleep therapy clinic is involved in a ... as interested in hearing from an employee of ... involved in a kickback scheme to provide medical practice ...
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/6/2017)... is Stroke Awareness Month and Omron Healthcare is reminding ... prevent a stroke: monitor and manage your blood pressure. ... undetected and uncontrolled hypertension is a leading risk factor ... personal heart health technology, recently evolved its mission to ... and is advancing a national public education effort to ...
Breaking Medicine Technology: